This research could also help us better understand how post-illness immunity works for COVID-19.
Researchers from the Peter Doherty Institute for Infections and Immunity received permission from the patient to participate in her research, along with a number of other subjects, and were able to collect blood samples showing how her immune responses worked and when they were activated. Doctors need time to treat severe cases while some of their peers attempt to develop vaccines or new drugs that will speed up the healing process. The peak of both ASCs and TFH cells was markedly higher in the patient with COVID-19 than in healthy control participants.
"It suggests to us that we can fight the virus and we can drive recovery from COVID-19", Prof Kedzierska said.
"We found in this patient three days after hospital admission we could see the emergence of specific cell populations in the blood", he added.
"We found that although COVID-19 is caused by a new virus, in a previously healthy patient robust immune responses can be elicited and associated with clinical recovery". ABC News Australia. "This information will allow us to evaluate any vaccine candidate because in an ideal world, the vaccine should mimic our body's immune response".
Working together with University of Melbourne Professor Katherine Kedzierska, a laboratory head at the Doherty Institute and a world-leading influenza immunology researcher, the team were able to dissect the immune response leading to successful recovery from COVID-19, which might be the secret to finding an effective vaccine.
According to the team, their research was facilitated by the Sentinel Travellers and Research Preparedness for Emerging Infectious Disease (SETREP-ID) platform which enables a broad range of biological sampling to take place in travellers returning to Australia when there is a new and unexpected infectious disease outbreak, such as COVID-19. Existing protocols helped them fast-track the research, saving precious time.
Revealed in Nature Medication is an in depth report of how the affected person's immune system responded to the virus. "Based on our experience with influenza patients, we could predict recovery, and that is exactly what happened at COVID-19".
However, most of the infected patients display mild symptoms, out of which only 20 per cent reach the critical stage.
"Then you could say upfront, this would be a severe case, or this will probably be a milder case", Dr van de Sandt said.
Dr Thevarajan stated that present estimates present greater than 80 p.c of COVID-19 circumstances are mild-to-moderate, and understanding the immune response in these gentle circumstances is essential to analysis.
But it is too early to tell whether getting COVID-19 once gives you immunity from getting it again.
Chris Smith started writing about gadgets as a hobby, and before he knew it he was sharing his views on tech stuff with readers around the world. But that is not necessarily a bad thing.